½Å»ý¾Æ ´ë»çÀÌ»ó ¼±º°°Ë»ç ÀÌ»óÀ¸·Î Áø´ÜµÈ IÇü ŸÀ̷νÅÇ÷Áõ
A Case with Tyrosinemia Type I Detected by Neonatal Screening Test

´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸÁö 2012³â 12±Ç 2È£ p.99 ~ p.103

¼Õ¿µ¹è(Sohn Young-Bae) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇÐÀ¯ÀüÇаú
ÀÌÇØ»ó(Lee Hae-Sang) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æû¼Ò³â°ú
ÀÌÀåÈÆ(Lee Jang-Hoon) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æû¼Ò³â°ú
ȲÁø¼ø(Hwang Jin-Soon) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æû¼Ò³â°ú

Abstract

IÇü ŸÀ̷νÅÇ÷ÁõÀº ŸÀ̷νÅÀÇ ºÐÇØ °úÁ¤ Áß ÃÖÁ¾´Ü°è¿¡ °ü¿©ÇÏ´Â È¿¼ÒÀÎ fumarylacetoacetate hydrolase (FAH)ÀÇ °áÇÌ¿¡ ÀÇÇÑ ´ë»ç ÀÌ»óÁúȯÀÌ´Ù. ±Þ¼º IÇü ŸÀ̷νÅÇ÷ÁõÀº Ä¡¸íÀûÀÎ °£ºÎÀüÀ̳ª Ç÷¾×ÀÀ°íÀå¾Ö¿Í °°Àº ±Þ¼º ÀÓ»óÁõ»óÀÌ ³ªÅ¸³­ ÀÌÈÄ¿¡´Â ¿¹ÈÄ°¡
ºÒ·®ÇÏ¿´À¸³ª ÃÖ±Ù¿¡´Â ½Å»ý¾Æ ´ë»çÀÌ»ó ¼±º°°Ë»ç¸¦ ÅëÇØ Á¶±â Áø´ÜÀÌ °¡´ÉÇØÁ³°í 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione nitisinone (NTBC) ¾à¹° Ä¡·á·Î ŸÀ̷νÅÇ÷ÁõÀÇ Ä¡·á ¼ºÀûÀÌ Çâ»óµÊ¿¡ µû¶ó ½Å»ý¾Æ ´ë»çÀÌ»ç ¼±º°°Ë»ç¸¦ ÅëÇÑ Á¶±â Áø´Ü°ú Á¶±â Ä¡·á°¡ ´õ¿í Áß¿äÇØÁ³´Ù°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ¿¡ ÀúÀÚµéÀº ½É°¢ÇÑ ÃâÇ÷À̳ª °£ºÎÀü°ú °°Àº ±Þ¼º ÀÌ»ó Áõ»óÀÌ ³ªÅ¸³ª±â Àü ½Å»ý¾Æ ´ë»çÀÌ»ó ¼±º°°Ë»ç·Î Á¶±â Áø´Ü ¹× Á¶±â ÁßÀçÀû Ä¡·á·Î ¾çÈ£ÇÑ °æ°ú¸¦ º¸ÀÌ°í ÀÖ´Â IÇü ŸÀ̷νÅÇ÷Áõ 1·Ê¸¦ °æÇèÇÏ¿´±â¿¡ ¹®Çå °íÂû°ú ÇÔ²² º¸°íÇÏ´Â ¹ÙÀÌ´Ù.
Tyrosinemia type I is an autosomal recessive inborn error of tyrosine metabolism that caused a mutation. Clinical symptoms include progressive liver damage with liver failure, coagulopathy, hypophosphataemic rickets, renal tubular dysfunction and a high risk of hepatocellular carcinoma. If left untreated, the affected infants may die from liver failure within the first year of life. PharmacoloIcal therapy with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) has offered an effective therapeutic option in addition to dietary restriction of tyrosine and phenylalanine. As prognosis of tyrosinemia type I is improving with early diagnosis and early treatments, it meets the criteria for a condition that would benefit from newborn screening. We report a case of tyrosinemia type I diagnosed by newborn screening and successive biochemical analysis of plasma and urine, treated by dietary restriction and NTBC.

Å°¿öµå

Tyrosinemia type I, Newborn screening, NTBC
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study reported a case of tyrosinemia type I diagnosed by newborn screening and successive biochemical analysis of plasma and urine, treated by dietary restriction and NTBC.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå